Home › Compare › BNOX vs EQR

BNOX vs EQR: Dividend Comparison 2026

BNOX yields 790.20% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BNOX wins by $2499878.53M in total portfolio value
10 years
BNOX
BNOX
● Live price
790.20%
Share price
$0.25
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2499878.58M
Annual income
$2,001,595,404,407.55
Full BNOX calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — BNOX vs EQR

📍 BNOX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBNOXEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BNOX + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
BNOX pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BNOX
Annual income on $10K today (after 15% tax)
$67,167.13/yr
After 10yr DRIP, annual income (after tax)
$1,701,356,093,746.42/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, BNOX beats the other by $1,701,356,089,092.15/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BNOX + EQR for your $10,000?

BNOX: 50%EQR: 50%
100% EQR50/50100% BNOX
Portfolio after 10yr
$1249939.31M
Annual income
$1,000,797,704,941.58/yr
Blended yield
80.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

BNOX
Analyst Ratings
4
Buy
Consensus: Buy
Price Target
$6.00
+2270.6% upside vs current
Range: $6.00 — $6.00
Altman Z
-82.3
Piotroski
5/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BNOX buys
0
EQR buys
0
No recent congressional trades found for BNOX or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBNOXEQR
Forward yield790.20% ✓5.87%
Annual dividend / share$2.00$3.47 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$2499878.58M ✓$47.8K
Annual income after 10y$2,001,595,404,407.55 ✓$5,475.61
Total dividends collected$2460392.87M ✓$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold
Analyst price target$6.00$70.35 ✓

Year-by-year: BNOX vs EQR ($10,000, DRIP)

YearBNOX PortfolioBNOX Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$89,720$79,020.15$11,380$679.82+$78.3K → BNOX
2$758,589$662,588.76$13,014$837.25+$745.6K → BNOX
3$6,047,418$5,235,727.31$14,961$1,036.20+$6.03M → BNOX
4$45,478,990$39,008,252.73$17,297$1,289.22+$45.46M → BNOX
5$322,828,490$274,165,970.92$20,121$1,613.15+$322.81M → BNOX
6$2,164,251,074$1,818,824,589.26$23,561$2,030.84+$2164.23M → BNOX
7$13,711,496,364$11,395,747,714.83$27,783$2,573.54+$13711.47M → BNOX
8$82,145,270,460$67,473,969,350.51$33,013$3,284.39+$82145.24M → BNOX
9$465,685,208,688$377,789,769,296.29$39,547$4,223.51+$465685.17M → BNOX
10$2,499,878,577,704$2,001,595,404,407.55$47,791$5,475.61+$2499878.53M → BNOX

BNOX vs EQR: Complete Analysis 2026

BNOX — Stock

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.

Full BNOX Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this BNOX vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BNOX vs SCHDBNOX vs JEPIBNOX vs OBNOX vs KOBNOX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.